Fourth-quarter events to watch for big pharma

Heading towards the end of 2020, a year dominated by Covid-19, Evaluate Vantage has delved into data releases expected from big pharma in the fourth quarter. Excluding readouts expected from coronavirus therapies and vaccines, oncology looks to dominate with Astrazeneca, Gilead, Takeda and Glaxosmithkline all due to unveil important updates.

Elsewhere Alzheimer’s comes into play for Roche, while both Bristol Myers Squibb and Pfizer have Tyk2 inhibitors in development for psoriasis, on which the first data are pending. The first look at Lilly's GIP/GLP-1 agonist tirzepatide should also emerge.